Immunogenicity and protective efficacy of a gE, gG and US2 gene-deleted bovine herpesvirus-1 (BHV-1) vaccine

E. B. Belknap, L. M. Walters, C. Kelling, V. K. Ayers, J. Norris, J. McMillen, C. Hayhow, M. Cochran, D. N. Reddy, J. Wright, J. K. Collins

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

The efficacy and safety of a gene-deleted bovine herpesvirus-1 (BHV-1) vaccine was determined in a bovine herpesvirus challenge trial in calves. Three different doses of the vaccine were administered intramuscularly at 105, 106 and 107 PFU/ml and compared to a commercial vaccine and non vaccinated control calves. Challenge was performed by intranasal aerosolization with the Cooper strain of BHV-1 (3 x 104 PFU/ml). The non- vaccinated calves shed significantly (P < 0.05) more virus than all other groups on days 4, 8 and 10 post challenge. By day 14 post challenge, antibody titers for BHV-1 of calves vaccinated with 107 PFU/ml were significantly (P < 0.05) higher than the commercial or non-vaccinated calves. Clinical scores of non-vaccinated calves were significantly (P < 0.05) higher than all other groups on days 4-14 post challenge. With both radioimmunoprecipitation and competitive enzyme-linked immunosorbent assays (C-ELISA), calves in the gene- deleted vaccine groups mounted comparable specific responses against gB, gC and gD post vaccination as calves in the commercial vaccine group, but in a dose dependent manner. These data suggest that the gene-deleted BHV-1 vaccine tested may be used as an effective vaccine in controlling BHV-1 infections.

Original languageEnglish (US)
Pages (from-to)2297-2305
Number of pages9
JournalVaccine
Volume17
Issue number18
DOIs
StatePublished - May 4 1999

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Immunogenicity and protective efficacy of a gE, gG and US2 gene-deleted bovine herpesvirus-1 (BHV-1) vaccine'. Together they form a unique fingerprint.

  • Cite this

    Belknap, E. B., Walters, L. M., Kelling, C., Ayers, V. K., Norris, J., McMillen, J., Hayhow, C., Cochran, M., Reddy, D. N., Wright, J., & Collins, J. K. (1999). Immunogenicity and protective efficacy of a gE, gG and US2 gene-deleted bovine herpesvirus-1 (BHV-1) vaccine. Vaccine, 17(18), 2297-2305. https://doi.org/10.1016/S0264-410X(98)00466-6